Skip to main content
  • Medicaid Provider Alert: Provider revalidation has begun and those not completing the process risk disenrollment.  Check your account now to learn when your revalidation is due. More information here.
Elizabeth M. Whitehorn, Director

Drugs and Therapeutics (D & T) Committee Drugs Under Review for: June 19, 2013

Drug Name Review Type Class Manufacturer
Invokana New Drug Initial Review SGLT2 Inhibitor Janssen
Pertzye New Drug Initial Review Pancreatic Enzyme Digestive Care, Inc
Vascepa New Drug Initial Review Lipotropic Amarin
Myrbetriq New Drug Initial Review Urinary Anti-Incontinence Agent Astellas Pharma
Tecfidera New Drug Initial Review Multiple Sclerosis Biogen Idec
Nesina New Drug Initial Review DPP-4 Inhibitor Takeda
Diclegis New Drug Initial Review Antiemetic Duchesnay USA
Tradjenta New Drug Appeal DPP-4 Inhibitor Boehringer-Ingelheim
Tudorza Pressair New Drug Appeal Long Acting Anticholingergic Forest
Stribild New Drug Appeal HIV/AIDS Gilead
Humatrope PDL Appeal Growth Hormone Eli Lilly